Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF JIANGZHONG PHARMACEUTICAL FOR THE THREE MONTHS ENDED 31 MARCH 2022

On 28 March 2022, Jiangzhong Pharmaceutical released its results estimate for the three months ended 31 March 2022.

Reference is made to the announcement dated 15 March 2022 made by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") in relation to the principal operating results estimate of Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司)(" **Jiangzhong Pharmaceutical**").

Jiangzhong Pharmaceutical is a company incorporated in the People's Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.03% equity interest by the Company through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司). The Group controls an effective interest of approximately 21.95% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

On 28 March 2022, Jiangzhong Pharmaceutical released its results estimate for the three months ended 31 March 2022. It was announced that, based on preliminary estimate, in the first quarter of 2022, the net profit attributable to shareholders of the listed company is expected to be approximately RMB183 million, representing a year-on-year increase of approximately RMB23 million (or a year-on-year increase of approximately 15%), and a net profit attributable to shareholders of the listed company (excluding non-recurring gains and losses) of approximately RMB172 million, representing a year-on-year increase of approximately RMB29 million (or a year-on-year increase of approximately 20%) (the "**Jiangzhong Results Estimate**").

Jiangzhong Pharmaceutical considered that its net profit attributable to shareholders of the listed company for the three months ended 31 March 2022 is expected to increase due to:

(i) The impact of its principal businesses: In the first quarter of 2022, Jiangzhong Pharmaceutical focused on its three major business priorities of "focusing on OTC, developing general health, and strengthening prescription drugs", strengthened brand building, expanded market layout, and maintained a good momentum in product sales. At the same time, having consolidated information of a newly acquired company (namely, Jincheng Hays Pharmaceutical Co., Ltd. (晉城海斯製藥有限公司)), Jiangzhong Pharmaceutical achieved good growth in its business performance.

(ii) The insignificant impact of non-operating profit and loss: In the first quarter of 2022, the non-operating profit and loss had no significant impact on the estimates of Jiangzhong Pharmaceutical's financial performance.

The Jiangzhong Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial information, those to be disclosed in the quarterly report for the three months ended 31 March 2022 to be issued by Jiangzhong Pharmaceutical shall prevail.

The financial information in this announcement is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 29 March 2022

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mdm. Weng Jingwen and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.